HCG in Research: Beyond Fertility Applications
Human chorionic gonadotropin (HCG) has a long research history outside fertility medicine, including studies in Leydig cell function, testosterone production support, and weight regulation hypotheses from the 1950s onward.
Research reference only. The information in this article is a summary of peer-reviewed scientific literature. It does not constitute medical advice and is not intended to guide human use. See our full disclaimer.
hCG Research: From HPT Axis Physiology to the Simeons Protocol Controversy
Human chorionic gonadotropin (hCG) is a glycoprotein hormone produced by trophoblastic cells during early pregnancy and by certain tumors, sharing structural homology with luteinizing hormone (LH), follicle-stimulating hormone (FSH), and thyroid-stimulating hormone (TSH). While hCG's roles in fertility medicine are well established through decades of controlled research, the compound has also been subject to scientifically unsupported claims — most prominently the Simeons weight-loss protocol — that have been systematically refuted in published randomized controlled trials. All content here summarizes peer-reviewed scientific literature for research reference purposes only; it does not constitute medical advice or guidance for human use.
Molecular Structure and Gonadotropin Family Context
hCG is a heterodimeric glycoprotein consisting of a 92-amino-acid alpha subunit — shared with LH, FSH, and TSH — and a 145-amino-acid beta subunit that confers receptor specificity. The beta subunit of hCG shares approximately 82% sequence homology with the LH beta subunit, which accounts for the compound's functional overlap with LH at the LH/hCG receptor (LHCGR). Unlike LH, hCG has an extended C-terminal peptide (CTP) on the beta subunit that contributes to its substantially longer circulating half-life (hours vs. minutes for LH), making hCG pharmacologically more useful for sustained receptor stimulation in research and clinical protocols.
The structural similarity among the glycoprotein hormone family — hCG, LH, FSH, TSH — was established through X-ray crystallography and mutagenesis studies (Lapthorn et al., Nature, 1994; Wu et al., Structure, 1994). This shared architecture, with a cystine-knot motif common to all family members, informs cross-reactivity considerations relevant to both research assay design and physiological function.
LH Receptor Agonism and Leydig Cell Stimulation
The LHCGR is a leucine-rich repeat-containing G protein-coupled receptor expressed primarily in Leydig cells of the testis and granulosa/luteal cells of the ovary, with lower-level expression documented in several other tissues. hCG binding to testicular LHCGR activates Gs-coupled cAMP/PKA signaling, which drives steroidogenesis through upregulation of StAR (steroidogenic acute regulatory protein) and the CYP450 enzyme cascade responsible for cholesterol-to-testosterone conversion.
Published dose-response studies in human males have characterized the testosterone-stimulating effects of exogenous hCG administration in controlled settings. Research data from hypogonadal men and from fertility medicine contexts establish that intramuscular or subcutaneous hCG reliably increases serum testosterone concentrations by stimulating Leydig cell steroidogenesis — a well-documented pharmacological effect that is mechanistically distinct from exogenous androgen administration because it operates through endogenous testicular production rather than exogenous hormone delivery.
This distinction has made hCG a research tool in studies of hypothalamic-pituitary-testicular (HPT) axis function, including investigations of Leydig cell reserve, spermatogenesis support during testosterone replacement, and the recovery of testicular function following suppression.
HPT Axis Research Applications
As an LH analogue with a longer half-life and convenient measurement in plasma (via beta-hCG immunoassay), hCG has been used extensively as a research tool in HPT axis studies. Published investigations have employed hCG stimulation tests to:
- Assess Leydig cell functional capacity in boys with suspected testicular disorders (Bertelloni et al., J Endocrinol Invest, multiple publications)
- Characterize the dose-response relationship between gonadotropin stimulation and testosterone secretion
- Evaluate fertility potential and testicular reserve in men with various forms of hypogonadism
- Investigate the kinetics of testosterone production and HPT feedback following exogenous gonadotropin stimulation
The hCG stimulation test remains a standard research and clinical assessment tool for gonadal function evaluation, with published normative data available across age groups and patient populations.
For the full compound profile, see the hCG library entry.
The Simeons Protocol: History and Scientific Refutation
In 1954, British physician Albert T.W. Simeons published a report in The Lancet proposing that daily low-dose hCG injections, combined with a very low calorie diet (VLCD, typically 500 kcal/day), produced superior weight loss and preferential mobilization of "abnormal fat deposits" compared to diet alone. This protocol became known as the Simeons protocol and was commercially propagated in various forms throughout subsequent decades.
Multiple randomized controlled trials published in peer-reviewed journals subjected the Simeons hypothesis to rigorous scientific testing. The most comprehensive evaluation was a double-blind, placebo-controlled study by Asher and Harper (Am J Clin Nutr, 1973), followed by additional controlled studies through the 1970s and 1980s. Collectively, these published RCT data failed to demonstrate any advantage for hCG over placebo in weight loss magnitude, fat distribution, hunger suppression, or body composition changes when both groups were maintained on the same caloric restriction.
A systematic review and meta-analysis published by Lijesen and colleagues (Br J Clin Pharmacol, 1995) analyzed the published controlled trial literature and concluded that "there is no scientific evidence that HCG is effective in the treatment of obesity; it does not bring about weight-loss of fat-redistribution, nor does it reduce hunger or induce a feeling of well-being." This remains the scientific consensus as documented in subsequent systematic review publications.
FDA Market Action and OTC Status
The scientific consensus against hCG for weight loss led to regulatory action in the United States. The FDA and Federal Trade Commission issued a joint statement in 1975 requiring hCG labeling to state explicitly that it has not been demonstrated to be an effective adjunct to dietary restriction in the treatment of obesity. Following the persistence of commercially sold "homeopathic hCG" products (which contained no detectable hCG by dilution), the FDA ordered the removal of these OTC products from the market in 2020, finding them both fraudulent and potentially harmful due to the associated extreme caloric restriction.
Legitimate pharmaceutical hCG formulations (prescription products, including Pregnyl and Novarel) retained their approval status for established fertility and reproductive medicine indications, which are distinct from the debunked weight-loss application.
Legitimate Fertility Research and Clinical Applications
The published research literature supporting hCG in fertility and reproductive medicine is extensive and methodologically robust. Established research and clinical applications include:
Ovulation induction: hCG serves as an LH surge surrogate to trigger final oocyte maturation and ovulation in assisted reproduction protocols. Published RCT data establish its efficacy in IVF and intrauterine insemination (IUI) protocols.
Male hypogonadotropic hypogonadism: In men with hypogonadism caused by inadequate LH secretion (hypogonadotropic hypogonadism, including Kallmann syndrome), hCG treatment restores testosterone production and supports spermatogenesis. Published studies characterize response rates and combination protocols with FSH.
Cryptorchidism research: hCG has been used in studies examining hormonal stimulation of testicular descent in cryptorchid males, with published pediatric endocrinology literature examining both efficacy and long-term outcomes.
Structural Homology Among Glycoprotein Hormones
The shared alpha subunit among hCG, LH, FSH, and TSH creates relevant considerations for research applications. Published studies have documented hCG's weak thyroid-stimulating activity through TSH receptor cross-activation, particularly at the very high concentrations achieved in gestational trophoblastic disease or hyperemesis gravidarum of pregnancy. This cross-reactivity with TSHR at supraphysiological hCG concentrations is clinically observed in research contexts and provides a naturally occurring model for studying TSH receptor activation through non-TSH ligands.
The structural and evolutionary conservation of the cystine-knot glycoprotein hormone family, and the promiscuity of receptor cross-activation at non-physiological concentrations, are active areas of interest in receptor structure-function research.
Research Use Only. This article summarizes published scientific literature for research reference purposes only. It does not constitute medical advice, and readers should not interpret discussion of the Simeons protocol as anything other than documentation of a refuted hypothesis.